Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TDP2 | O95551 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | GALK1 | P51570 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.32 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.32 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1759000 | 1.00 | EGFR (0.35) | EGFRERBB2KDM1AIDO1KDM4E | |
| SCHEMBL568314 | 1.00 | EGFR (0.35) | EGFRERBB2KDM1AIDO1KDM4E | |
| SCHEMBL1680560 | 0.91 | EGFR (0.39) | EGFRERBB2KDM1AIDO1KDM4E | |
| SCHEMBL9985983 | 0.89 | EGFR (0.36) | EGFRERBB2KDM1AIDO1ALDH1A1 | |
| SCHEMBL1578331 | 0.88 | — | — | |
| SCHEMBL5700201 | 0.80 | EGFR (0.34) | EGFRERBB2KDM1AKDM4ETDP2 | |
| SCHEMBL2155195 | 0.79 | KDM1A (0.43) | EGFRERBB2KDM1AIDO1KDM4E | |
| SCHEMBL18980719 | 0.78 | KDM4E (0.34) | EGFRERBB2KDM1AKDM4ESLC6A4 | |
| SCHEMBL5609115 | 0.78 | KDM1A (0.33) | KDM1AIDO1KDM4EALDH1A1SLC6A4 | |
| SCHEMBL7775994 | 0.76 | KDM1A (0.38) | EGFRERBB2KDM1AIDO1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 587 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220033391-A1 | SOLID FORM, CRYSTALLINE FORM, AND CRYSTAL FORM A OF FXR AGONIST, AND PREPARATION METHOD AND APPLICATION THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2022-02-03 | — | — | US | claimed |
| EP-2708527-B1 | ALDEHYDE COMPOUND PRODUCTION METHOD | MITSUI CHEMICALS INC (JP) | 2019-03-20 | — | — | EP | claimed |
| US-20170173572-A1 | CHIRAL LIGAND-BASED METAL-ORGANIC FRAMEWORKS FOR BROAD-SCOPE ASYMMETRIC CATALYSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-06-22 | — | — | US | claimed |
| US-9227925-B2 | Process for producing aldehyde compounds | MITSUI CHEMICALS, INC. (JP) | 2016-01-05 | — | — | US | claimed |
| US-12637421-B2 | Anthraquinone compound, liquid crystal composition containing said compound, and dimming element | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2026-05-26 | — | — | US | disclosed |
| US-12612410-B2 | Multi-cyclic IRAK and FLT3 inhibiting compounds and uses thereof | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4725942-A1 | COMPOUNDS ACTIVE ON CYCLIN D1 PATHWAY AND THEIR USE | Sibylla Biotech S.p.A. (IT) | 2026-04-15 | — | — | EP | disclosed |
| US-20260042755-A1 | GPR6 INVERSE AGONISTS | MAPLIGHT THERAPEUTICS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-20260027113-A1 | PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE | SOLEY THERAPEUTICS INC (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4658659-A2 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | Children's Hospital Medical Center (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20250368648-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2025-12-04 | — | — | US | disclosed |
| US-12465603-B2 | Phthalazinone based modulators for the treatment of disease | SOLEY THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| EP-0295109-B2 | Process for preparing optically active alcohol | TAKASAGO PERFUMERY CO LTD (JP) | 1996-09-04 | — | — | EP | disclosed |
| EP-0403188-B1 | A compound of 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl and catalytic complexes thereof | TAKASAGO PERFUMERY CO LTD (JP) | 1994-12-07 | — | — | EP | disclosed |
| EP-0297752-B1 | PROCESS OF PREPARING OPTICALLY ACTIVE ALCOHOL | Takasago International Corporation (JP) | 1992-09-16 | — | — | EP | disclosed |
| EP-0403188-A3 | A COMPOUND OF 2,2'-BIS(DIPHENYLPHOSPHINO)-1,1'-BINAPHTHYL AND CATALYTIC COMPLEXES THEREOF | Takasago International Corporation (JP) | 1991-08-28 | — | — | EP | disclosed |
| EP-0403188-A2 | A compound of 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl and catalytic complexes thereof | Takasago International Corporation (JP) | 1990-12-19 | — | — | EP | disclosed |
| US-4933482-A | HYDROGENATION OF BETA-KETO ACID IN PRESENCE OF RUTHENIUM PHOSPHINE COMPLEX | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1990-06-12 | — | — | US | disclosed |
| US-4916252-A | OPTICALLY ACTIVE PHOSPHINE-RUTHENIUM HYDROGENATION CATALYST | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1990-04-10 | — | — | US | disclosed |
| EP-0297752-A2 | Process of preparing optically active alcohol | Takasago International Corporation (JP) | 1989-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033391-A1 | SOLID FORM, CRYSTALLINE FORM, AND CRYSTAL FORM A OF FXR AGONIST, AND PREPARATION METHOD AND APPLICATION THEREOF | SLC10A1, FXR1, NR1H4 | EGFR 1510/4885ERBB2 3559/4885KDM1A 3934/4885 |
| US-20170173572-A1 | CHIRAL LIGAND-BASED METAL-ORGANIC FRAMEWORKS FOR BROAD-SCOPE ASYMMETRIC CATALYSIS | POF1B, FGFR1, COASY | EGFR 302/4885ERBB2 841/4885KDM1A 1675/4885 |
| US-12465603-B2 | Phthalazinone based modulators for the treatment of disease | MKI67, BCL2, CCAR2 | EGFR 728/4885ERBB2 340/4885KDM1A 1073/4885 |
| US-20260027113-A1 | PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE | NCOR1, NOP56, NCOR2 | EGFR 182/4885ERBB2 265/4885KDM1A 2756/4885 |
| US-20260042755-A1 | GPR6 INVERSE AGONISTS | GPR6, GPR3, GPR4 | EGFR 378/4885ERBB2 703/4885KDM1A 4043/4885 |
| US-12637421-B2 | Anthraquinone compound, liquid crystal composition containing said compound, and dimming element | ACIN1, ANTXR2, CXCR1 | EGFR 4517/4885ERBB2 3702/4885KDM1A 1159/4885 |
| US-12612410-B2 | Multi-cyclic IRAK and FLT3 inhibiting compounds and uses thereof | FLT3, IRAK3, IRAK2 | EGFR 523/4885ERBB2 111/4885KDM1A 305/4885 |
| US-20250368648-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | FLT3, IRAK1, IRAK2 | EGFR 241/4885ERBB2 103/4885KDM1A 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.